<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Wnt signaling decreases the recruitment of RAB8a to basal bodies. by Cheng Yuan (160315)

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Subjects: “…chronically infected patients…”

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

Table of step height. by Jianbo Jia (717814)

“…Finally, by making corresponding test blocks, it was found that the peak value of forward resistance when the 10.5°test block crossed the steps of 1mm, 2mm and 3mm height decreased by 19.8%, 25.0% and 13.9% respectively, and the mean value decreased by 30.8%, 27.2% and 24.1% respectively, which was close to the simulation results, and verified the accuracy of the finite element analysis results.…”

The well wall step. by Jianbo Jia (717814)

“…Finally, by making corresponding test blocks, it was found that the peak value of forward resistance when the 10.5°test block crossed the steps of 1mm, 2mm and 3mm height decreased by 19.8%, 25.0% and 13.9% respectively, and the mean value decreased by 30.8%, 27.2% and 24.1% respectively, which was close to the simulation results, and verified the accuracy of the finite element analysis results.…”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…<p>Confocal microscopy images of heart sections incubated with specific antibodies against VCAM-1 <b>(A)</b>, tubulin <b>(B)</b> and dynein <b>(C)</b> showed a decrease in fluorescence signals in samples from the EVs and ICs groups. …”

Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects: